4 minute read
Allergan Aesthetics publishes ‘The Future of Aesthetics’
REPORT AIMS TO HELP SUPPORT THE EVOLVING NEEDS OF PATIENTS
Allergan Aesthetics, an AbbVie company, and a global leader in medical aesthetics treatments, has announced the U.S. publication of ‘The Future of Aesthetics’ global trends report, developed to understand what is shaping the aesthetics industry of tomorrow.
Consumer interest in medical aesthetics continues to rise, and the growth rate of the North American medical aesthetics market is expected to accelerate to more than 10% annually through 2026. The number and type of non-surgical aesthetic procedures conducted worldwide grew by nearly two million between 2017 and 2020. This growth is expected to continue, with 23 million dermal fillers and 14.6 million body procedures predicted by 2025. In parallel, physicians globally saw an increased volume of younger patients, more patients from a diverse range of ethnic backgrounds, and more male patients than ever before.
‘Aesthetics is a dynamic industry, which must continually adapt and evolve with changing habits and shifting cultural norms. Our trends report—The Future of Aesthetics report—builds on insights uncovered in the 2019 Allergan 360 Aesthetics Report™ on evolving beauty perceptions and diverse priorities around the world,’ commented Carrie Strom, President, Global Allergan Aesthetics. ‘We recognise the fast-moving nature of aesthetics and are committed to furthering research and innovation in our field. Our research on the evolution of consumer preferences aims to support practitioners to better meet future patient needs. Thank you to our partners who participated in this important study.’ Exploring the underlying themes and trends for modern aesthetics The research identified key themes driving the future of aesthetics including: Aesthetic Fluency, De-stigmatising Treatments and a desire to move Back to Nature. Resulting from these are 10 major trends, which will likely drive medical aesthetics practice in the coming years. By acknowledging changes in the industry, clinicians may be able to educate and communicate with patients more effectively. Renowned board-certified dermatologist, Elizabeth Hale says: ‘Recently, I have witnessed the evolution of the “aesthetic patient” to one that is much more diverse, knowledgeable and vocal about their needs. “The Future of Aesthetics” report provides research-driven and anecdotal observations to help health care providers prepare for the continued growth of the aesthetics industry and prepare for modern-day patients.’ Brought to you by some of the world’s leading practitioners The Future of Aesthetics report, commissioned by Allergan Aesthetics and independently developed by Wunderman Thompson Intelligence, is informed by extensive research and analysis across consumer and business media, social listening data, and market
Consumer interest in medical aesthetics research from around the globe that was validated through continues to rise, and the one-on-one interviews growth rate of the North with 15 leading American medical aesthetics practitioners†. The Future of aesthetics market is Aesthetics report expected to accelerate to provides a unique view more than 10% annually of what tomorrow holds for the aesthetics through 2026. industry. To access The Future of Aesthetics report and for more information, please visit news.allerganaesthetics.com/future-ofaesthetics to register your interest in receiving the report.
AVÉLI™ RECEIVES EXTENDED FDA CLEARANCE
Revelle Aesthetics, Inc. (Revelle)—a VC-backed Silicon Valley MedTech company—achieved an extended FDA clearance for its precision cellulite release device, Avéli™. Marking another key milestone for the Company, Avéli is now indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating treatment benefits through one year of observation.
‘For far too long, millions of women have struggled to feel comfortable in their own skin because of their cellulite and have been settling for less than effective treatment options. Avéli is setting out to change this by finally providing women with a meaningful and lasting solution that targets their cellulite in the areas that have frustrated them the most, their buttocks and thighs,’ said Caroline Van Hove, President and CEO of Revelle Aesthetics. ‘Equally as exciting is the role that we believe Avéli will play as a cornerstone in the latest and fastest growing category in medical aesthetics, lower body rejuvenation.’
Cellulite is a depression of any shape or size with a defined edge, typically on the buttocks or thighs, and affects up to 90% of women. A major underlying cause of cellulite is the complex structure of fibrous septa bands that tether the skin. Some septa stiffen or shrink over time and lead to the dimples we see on the skin’s surface.
Unlike many current cellulite options, Avéli addresses cellulite from the inside-out. It is the only minimally invasive procedure that allows a provider to identify which of the fibrous septa bands are causing a cellulite dimple, and then confirm in real-time they are releasing those targeted septa to deliver visibly smoother skin. Results are visible quickly after a single in-office procedure with little-to-no downtime.
Avéli is now available across the US, growing rapidly in plastic surgery and dermatology practices that are focused on the rising needs in body contouring.
